Sentiment Index
Biopharma
Biopharmaceuticals sentiment held near 41, with 10 of 13 companies having reported, masking significant differences across the sector. Strong earnings, improving guidance and new product launches supported sentiment at AbbVie, Johnson & Johnson, Gilead and Eli Lilly, while Vertex and Novartis saw sharp declines.
AbbVie's improving immunology outlook and Johnson & Johnson's launch-driven growth provided bright spots, while Novartis faced generic competition for Entresto and Vertex's higher guidance was driven by an acquisition rather than stronger underlying demand. The key question is whether new launches and pipeline progress can offset patent expirations, rising costs and growing competition heading into 2027.
This preliminary reading reflects 10 of 13 companies reporting. The index will be updated as the remaining companies report.
The AlphaSense Sentiment Score is calculated as the net sum of positive and negative discourse in public company earnings call transcripts. It is powered by the AlphaSense Sentiment language model that applies deep domain-aware semantic reasoning to financial disclosure commentary and dialogue. It identifies significant shifts in executive tone and intent down to the sentence level, highlighted and auditable in all transcripts within the AlphaSense platform. This model delivers a normalized sentiment score (-100 to 100) that allows the tracking and identification of sentiment shifts based on what executives across thousands of public companies are discussing on earnings calls.
Transform intelligence
into advantage
Develop bold strategies, seize opportunities, and lead with clarity and confidence.